Royal Philips showcased its line of interventional cardiology products at the European Association of Percutaneous Cardiovascular Interventions’ EuroPCR Annual Congress in Paris last week. Such systems are being utilized to treat and detect coronary, peripheral, and structural heart diseases, Philips officials say.
Bert van Meurs, CEO of Philips’ image-guided therapy business, says one major growth area in the interventional cardiovascular field is image-guided therapy. “The broad portfolio of Philips Volcano solutions has begun personalizing the future of minimally invasive procedures for every patient,” he adds, remarking that the products exhibited at the Parisian conference “bring to life our integrated solutions and strategies for interventional cardiology to optimize outcomes while managing costs.”
Philips’ image-guided interventional systems span the x-ray and transesophageal echocardiography (TEE) ultrasound fields, with key technologies including AlluraClarity with ClarityIQ and HeartNavigator. The former product is a low-dose interventional x-ray system while the latter software expedites the planning, measurement, device selection, and choice of x-ray viewing angle for transcatheter aortic valve implantation, left atrial appendage, mitral, and other structural heart disease procedures.
Other technologies Philips showcased at EuroPCR 2016 include EchoNavigator, which fuses 3D TEE and x-ray in real time to provide live image guidance in the 3D space, and IntelliSpace Cardiovascular—an image management system that enables clinicians to analyze, access, and regulate cardiovascular information from a single workspace.
For more information about these products, visit Royal Philips.